Health Topic

Transfusion Safety

Committed to the prevention of transfusion-transmitted infections

Roche is committed to developing blood safety solutions that reach the highest possible standards. We are dedicated to ensure the safety of patients, the reliability of results and efficiency of lab operations, while helping laboratories make the best use of their available resources.

Blood is a crucial healthcare resource that can save lives. Every year worldwide there are over 164 million blood and plasma donations that are commonly used in supportive care for cardiovascular and transplant surgery patients, trauma victims, and those undergoing cancer therapy.1,2 Ensuring access to a sufficient and safe supply of blood and blood-derived products is an international health priority that has been highlighted by the World Health Organization since 1975.3

Roche is a trusted partner for screening centers, with about one third of blood and plasma donated worldwide using blood safety solutions from Roche.4


One blood donation has the potential to save 3 lives5


Blood transfusion safety relies heavily on the accurate and timely screening of blood for transmissible infections. In addition, pathogens evolve and new ones emerge, demanding the need for continuous and robust test innovation and development.


Striving for continual improvement to meet evolving needs

Roche Diagnostics offers a comprehensive portfolio of infectious diseases assays along the continuum of care, thereby enabling laboratories to provide the right information, from screening and diagnosis to patient management and treatment monitoring.

Our complete Infectious Diseases offer includes serology and also molecular testing which, thanks to our Personalized Lab Automation solutions can be configured, connected and integrated to suit the requirements of any laboratory.

Each Roche Diagnostics infectious diseases test is designed with a clinical benefit in mind. For example, the CMV tests allow for a reliable discrimination between an acute and a remote infection, therefore preventing unnecessary repeat testing6.

Our extensive infectious diseases portfolio is expanding every year. We are not only focusing on launching new parameters but we are also continuously updating our existing portfolio seeking continuous improvement, as well as keeping pace with the evolution of pathogens.

Roche blood safety solutions are designed to work together

Roche offers the most comprehensive screening solution for blood safety and draws from three areas of Roche expertise. Roche is the only single provider for serology, NAT, lab automation and software solution to blood centers and plasma fractionators worldwide. Our market-leading serology and  NAT testing and our unique Laboratory Automation solutions can optimize your productivity no matter how large or small your operation may be.

Products of the Roche blood safety solutions portfolio are not commercially available in all regions. Please contact your local Roche representative regarding availability.
  1. World Health Organization. Blood Safety and Availability 2017. Retrieved 18 June 2018 from:
  2. Plasma Protein Therapeutics Association 2017. Retrieved 18 June 2018 from:
  3. World Health Organization. Global Status Report on Blood Safety and Availability 2016.
  4. Data on file.
  5. American Red Cross Blood Services. Retrieved on 18 June 2018 from:
  6. Revello, M.G. et al. (2012). Eur J Clin Microbiol Infect Dis. (CMV)
Found 0 results in